Lexicon Pharmaceuticals
LXRXLXRX · Stock Price
Historical price data
Overview
Lexicon Pharmaceuticals has successfully transitioned from a discovery-focused research organization to a commercial-stage biopharma company following the FDA approval of INPEFA® for heart failure in May 2023. Its core strategy is built upon a systematic, genetics-driven discovery platform that validates novel drug targets in vivo, aiming to de-risk development and deliver first-in-class therapeutics. The company's mission is to address significant unmet medical needs, with current efforts centered on commercializing INPEFA and advancing late-stage candidates like LX9211 for neuropathic pain. Lexicon's future hinges on executing its commercial launch, expanding INPEFA's label, and translating its unique platform into additional high-value clinical assets.
Technology Platform
Proprietary large-scale gene knockout technology that systematically inactivates genes in model organisms to identify and validate novel drug targets through comprehensive in vivo phenotypic screening.
Pipeline
49| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Sotagliflozin + Placebo | Obstructive Cardiomyopathy, Hypertrophic | Phase 3 | |
| Telotristat etiprate + Placebo-matching telotristat etiprate | Carcinoid Syndrome | Phase 3 | |
| Telotristat etiprate | Carcinoid Syndrome | Phase 3 | |
| Telotristat etiprate + Placebo | Carcinoid Syndrome | Phase 3 | |
| Sotagliflozin Low Dose + Sotagliflozin High Dose | Type 1 Diabetes (T1D) | Phase 3 |